EGFR and non-small cell lung carcinoma: Another multicenter dual arm phase II trial (NCT05167851) aims to investigate the clinical efficacy and safety of Lazertinib combined with early local ablation radiotherapy in patients with EGFR mutated NSCLC with simultaneous oligometastatic disease (35).